Literature DB >> 2790789

Prognostic factors in inoperable adenocarcinoma of the lung: a multivariate regression analysis of 259 patients.

J B Sørensen1, J H Badsberg, J Olsen.   

Abstract

The prognostic factors for survival in advanced adenocarcinoma of the lung were investigated in a consecutive series of 259 patients treated with chemotherapy. Twenty-eight pretreatment variables were investigated by use of Cox's multivariate regression model, including histological subtypes and degree of differentiation, the new international staging system for lung cancer, and seven laboratory parameters. Staging of the patients included bone marrow examination but were otherwise nonextensive without routine bone, liver, and brain scans. Factors predicting poor survival were low performance status, stage IV disease, no prior nonradical resection, liver metastases, high values of white blood cell count, and lactate dehydrogenase, and low values of asparatate aminotransaminase. The nonradical resection may not be a prognostic factor because of the resection itself but may rather serve as an indicator for patients having minimal disease spread. Liver metastases were of limited clinical value as a prognostic factor because they were detected in only seven cases in this patient population. A new Cox analysis ignoring the influence of this variable revealed no other variables than those occurring in the former Cox model to be of importance (performance status, stage, surgical resection, WBC, aspartate aminotransaminase, and lactate dehydrogenase). This simplified model appears to be a feasible clinical tool, allowing for prognostic stratification of patients when first the inoperability of the patient is known.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2790789

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Phase II study of teniposide in adenocarcinoma of the lung.

Authors:  J B Sørensen; F Bach; P Dombernowsky; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  [Survival time of exclusively irradiated NSCLC patients: the viewpoint of a clinical biologist. Concerning the article by R. Wilhelm et al in Strahlenther Onkol 1988: 174:128-32 (No. 3)].

Authors:  J Watine; R Fintelmann; J C Charet
Journal:  Strahlenther Onkol       Date:  1999-01       Impact factor: 3.621

3.  Pretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapy.

Authors:  Branislav Jeremic; Biljana Milicic; Aleksandar Dagovic; Jasna Aleksandrovic; Nebojsa Nikolic
Journal:  J Cancer Res Clin Oncol       Date:  2003-03-07       Impact factor: 4.553

4.  Sexual activity and body image: examining gender variability and the influence of psychological distress in cancer patients.

Authors:  Jessica Krok; Tamara Baker; Susan McMillan
Journal:  J Gend Stud       Date:  2013-10-01

5.  [Prognosis after surgical treatment of spinal metastases due to lung cancer].

Authors:  C Hessler; J Regelsberger; F Raimund; O Heese; J Madert; C Eggers
Journal:  Chirurg       Date:  2008-07       Impact factor: 0.955

6.  Substantial risk affects the stage-dependent outcomes of cisplatin-based adjuvant chemotherapy for completely resected non-small cell lung cancer.

Authors:  Ichiro Yoshino
Journal:  Surg Today       Date:  2013-02-11       Impact factor: 2.549

7.  A prognostic-factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy.

Authors:  T Shinkai; K Eguchi; Y Sasaki; T Tamura; Y Ohe; A Kojima; F Oshita; T Miya; H Okamoto; K Iemura
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Performance status assessment in cancer patients. An inter-observer variability study.

Authors:  J B Sørensen; M Klee; T Palshof; H H Hansen
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

9.  Prognostic factors for short-term survival in patients with stage IV non-small cell lung cancer.

Authors:  M Ando; Y Ando; S Sugiura; H Minami; H Saka; S Sakai; K Shimokata; Y Hasegawa
Journal:  Jpn J Cancer Res       Date:  1999-02

10.  Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?

Authors:  P J Ross; S Ashley; A Norton; K Priest; J S Waters; T Eisen; I E Smith; M E R O'Brien
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.